Previous 10 | Next 10 |
Intercept Pharmaceuticals, Inc. (ICPT) Q4 2018 Results Conference Call February 28, 2019 08:30 AM ET Company Participants Mark Vignola - Executive Director, Corporate Development and IR Dr. Mark Pruzanski - CEO Jerry Durso - COO Sandip Kapadia - CFO Conference Call Particip...
Quick Take Genfit S.A. ( GNFT ) intends to raise $100 million in an IPO of ADSs representing ordinary shares, according to an F-1 registration statement . The firm is developing treatment candidates for non-alcoholic steatohepatitis [NASH] conditions. GNFT says it expects results from i...
Sequential Brands (NASDAQ: SQBG ) +52% as Martha Stewart to advise Canopy Growth and Sequential Brands on CBD marketing . More news on: Sequential Brands Group, Inc., Arcadia Biosciences, Horizon Pharma plc, Stocks on the move, Read more ...
Intercept's data in NASH fibrosis get a muted reception Intercept Pharmaceuticals ( ICPT ) last week announced data from its pivotal REGENERATE PhIII trial evaluating lead drug obeticholic acid ('OCA'), currently marketed as OCALIVA , in patients with liver fibrosis due to NASH. OCA has r...
Intercept Pharma ( ICPT ) Q4 results : Revenues: $53.3M (+41.4%); Product revenue: $52.9M (+42.2%); Licensing revenue: $0.41M (-8.9%). More news on: Intercept Pharmaceuticals, Healthcare stocks news, Earnings news and commentary, Read more ...
Intercept Pharma (NASDAQ: ICPT ): Q4 GAAP EPS of -$2.97 misses by $0.47 . More news on: Intercept Pharmaceuticals, Earnings news and commentary, Healthcare stocks news, Read more ...
Positive topline results from pivotal Phase 3 REGENERATE study of obeticholic acid in patients with liver fibrosis due to NASH: the largest and first successful pivotal Phase 3 NASH study Worldwide Ocaliva net sales of $52.9 million in the fourth quarter of 2018 and $177.8 mill...
AAON , ABB , ACIW , AKRX , AMCX , AMRX , BCPC , BID , BMCH , BPMP , BUD , CARS , CM , CMD , CNP , CROX , CWEN , CWT , DAVA , DEA , EGRX , ENDP , EXLS , FOLD , FRO , FSS , GOLF , GTN , GTT , HMHC , HRI , IBP , ICPT , IRDM , JCP , JD , KDP , LAUR , LKQ ,...
Background NASH, or nonalcoholic steatohepatitis, has only been widely recognized as a disease for a short time. It may be more than one disease, given that it is defined as fatty, inflamed liver that is not due to alcohol abuse. Being a "not" condition implies that sub-types may exist. Ev...
Alexion Pharmaceuticals (NASDAQ: ALXN ) initiated with Neutral rating and $135 (6% upside) price target at Guggenheim. More news on: Alexion Pharmaceuticals, Inc., Dermira, Exelixis, Inc., Healthcare stocks news, Stocks on the move, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
Intercept Pharmaceuticals Inc. Company Name:
ICPT Stock Symbol:
NASDAQ Market:
Intercept Pharmaceuticals Inc. Website:
MORRISTOWN, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc., a biopharmaceutical company and wholly owned subsidiary of Alfasigma S.p.A. focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, today announced five abs...
sNDA intended to satisfy post-marketing requirements to confirm a clinical benefit in patients with PBC Precedent-setting submission includes data from post-marketing studies COBALT and Study 401 as well as real-world evidence from a claims database and patient registries FDA has assign...
Data from two Phase 2 studies in PBC show combination of OCA + bezafibrate achieved biochemical remission (normalization of ALP, total bilirubin, GGT, ALT and AST) in 40-44% of patients in the first 12 weeks OCA 5 or 5-10 mg + bezafibrate 400 mg cohorts in both studies showed a >60% ...